MDIT — Medite Cancer Diagnostics Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -30.81% | ||
| Return on Equity | -86.46% | ||
| Operating Margin | -49.34% | ||
Financial Summary
| Year End 31st Dec | Unit | 2013 | 2014 | 2015 | 2016 | 2017 | 2018E | 2019E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 9.96 | 10.98 | 9.89 | 9.24 | 6.81 | n/a | n/a | 102.92% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MEDITE Cancer Diagnostics, Inc. (MEDITE) is a medical technology company specialized in the development, manufacturing, and marketing of premium medical devices, consumables and molecular biomarkers for detection, risk assessment and diagnosis of cancerous and precancerous conditions and related diseases. The Company also develops, manufactures, markets, and sells MEDITE branded products (instruments and consumables), in the areas of histology and cytology. The Company has a distribution network to over 80 countries and a range of products for anatomic pathology, histology and cytology laboratories available for sale. The Company’s subsidiaries consist of MEDITE Enterprise, Inc., MEDITE GmbH, Burgdorf, Germany and MEDITE Lab Solutions Inc.
Directors
- William Lewis NEC (45)
- Michaela Ott COO (55)
- Jeff Rencher CMO (53)
- Gregory Fortunoff DRC (51)
- John Abeles IND (75)
- Joel Kanter IND (62)
- Alexander Milley IND (69)
- Last Annual
- December 31st, 2017
- Last Interim
- September 30th, 2018
- Incorporated
- December 15th, 1998
- Public Since
- October 27th, 1993
- No. of Employees
- 5
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 86,723,700
- Address
- 414 N Orleans St Ste 502, CHICAGO, 60654-4498
- Web
- http://www.medite-group.com/
- Phone
- +1 4078490290
- Auditors
- Withum- Smith & Brown
Upcoming Events for MDIT
Similar to MDIT
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
Aksys
Pink Sheets on Nasdaq
FAQ
As of Today at 19:14 UTC, shares in Medite Cancer Diagnostics are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Medite Cancer Diagnostics last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Medite Cancer Diagnostics share price has underperformed the S&P500 Index by -13.63% over the past year.
There is no consensus recommendation for this security.
Medite Cancer Diagnostics does not currently pay a dividend.
Medite Cancer Diagnostics does not currently pay a dividend.
Medite Cancer Diagnostics does not currently pay a dividend.
To buy shares in Medite Cancer Diagnostics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Medite Cancer Diagnostics had a market capitalisation of .
Here are the trading details for Medite Cancer Diagnostics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: MDIT
Based on an overall assessment of its quality, value and momentum Medite Cancer Diagnostics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medite Cancer Diagnostics. Over the past six months, its share price has underperformed the S&P500 Index by -16.56%.
As of the last closing price of $0.00, shares in Medite Cancer Diagnostics were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Medite Cancer Diagnostics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Medite Cancer Diagnostics' management team is headed by:
- William Lewis - NEC
- Michaela Ott - COO
- Jeff Rencher - CMO
- Gregory Fortunoff - DRC
- John Abeles - IND
- Joel Kanter - IND
- Alexander Milley - IND